NCT06091917

Brief Summary

In this study, betaine intake will be increased in formula-fed infants through formula milk supplementation. To do this, a double-blind randomized study has been designed with the supplementation group (infant formula supplemented with betaine) and control group (unsupplemented infant formula). The main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Oct 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Oct 2023Dec 2026

First Submitted

Initial submission to the registry

October 13, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 19, 2023

Completed
12 days until next milestone

Study Start

First participant enrolled

October 31, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

2.6 years

First QC Date

October 13, 2023

Last Update Submit

March 19, 2026

Conditions

Keywords

Betaineinfant formulachildhood obesity riskinfant growthone-carbon metabolism

Outcome Measures

Primary Outcomes (2)

  • Change in weight-for-length z score

    Weight and length will be measured at different time-points and combined to calculate weight-for-length z scores.

    From start to the end of treatment at 12 weeks and at 12 months of follow-up

  • Changes in fecal microbiota composition

    Differences in features associated with a healthy mucosal layer and metabolic state (e.g. Bifidobacteria and Akkermansia relative amount). Stool samples will be processed to isolate the bacterial DNA. Microbiome composition will be determined by DNA sequencing.

    At 4 weeks and 12 weeks end of treatment, and at 12 months of follow-up

Secondary Outcomes (2)

  • Infant body composition

    At 12 months of follow-up

  • Urine one-carbon metabolite concentration

    At 4 weeks and 12 weeks after start of treatment

Other Outcomes (1)

  • Infant's DNA methylome

    At the end of the 12-week treatment

Study Arms (2)

Control group

SHAM COMPARATOR

Use of unmodified infant formula for 12 weeks

Dietary Supplement: Regular infant formula

Betaine supplementation group

EXPERIMENTAL

Use of infant formula supplemented with betaine (final concentration of 100 µmol/L) for 12 weeks

Dietary Supplement: Betaine supplementation in infant formula

Interventions

Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.

Betaine supplementation group
Regular infant formulaDIETARY_SUPPLEMENT

Regular (unmodified) infant formula . The intervention will last for 12 weeks.

Control group

Eligibility Criteria

Age0 Weeks - 4 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Maternal age between 17 and 42 years
  • Maternal pre-pregnancy BMI equal or higher than 25
  • Gestational age at birth \> 37 weeks
  • No exclusive breastfeeding at time of recruitment

You may not qualify if:

  • Presence of disease or malformations in the infant
  • Infant birth weight \< -1 SD (standard deviations)
  • Multiple pregnancy
  • Elective c-section

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Sant Joan de Déu

Barcelona, Barcelona, 08950, Spain

Location

MeSH Terms

Conditions

Pediatric Obesity

Interventions

Infant Formula

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Milk SubstitutesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood, FormulatedFoods, SpecializedFoodInfant FoodFood and Beverages

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 13, 2023

First Posted

October 19, 2023

Study Start

October 31, 2023

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

March 20, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations